Hikma Pharmaceuticals PLC (LSE:HIK) - Share price


Stock Report

Hikma Pharmaceuticals PLC HIK

Last Price
GBX2,224.00

Day Change
28.00|1.28%

As of 06/07/2020
17:49:41 BST | GBX
Minimum 15 Minutes Delay.

Last Close2,196.00p
Day Range2,104.00 - 2,224.00
Mkt Cap5.06Bil
52-Wk Range1,596.00 - 2,670.00
Yield %1.71
ISINGB00B0LCW083
Volume785,433
P/E13.95
P/S2.45
P/CF11.45

Share Price

Total Returns 03/07/2020

 Chg (%)  
More ...
Hikma Pharmaceuticals PLC-1.92 
FTSE 100 TR GBP2.09
 
Financials
201720182019
More ...
Income Statement
Turnover1,936.002,070.002,207.00
Operating Profit323.00371.00450.00
Net Profit-839.00285.00487.00
Reported EPS-3.511.172.00
Balance Sheet
Current Assets1,574.001,668.001,848.00
Non Current Assets1,814.001,829.002,082.00
Total Assets3,388.003,497.003,930.00
Current Liabilities797.00893.001,471.00
Total Liabilities---
Total Equity1,528.001,697.002,129.00
Cash Flow
Operating Cash Flow443.00430.00472.00
Net Change in Cash72.0056.00166.00

Regulatory News

DateAuthor Headline
01/11/2017Emma Simon Investor Views: "I Doubled My Money Investing in Gold"
Private investor Eric Vale made strong gains from gold miner Fresnillo, but has seen his pharmaceutical stocks falter
11/09/2017Emma Wall 3 Undervalued UK Stocks
The FTSE 100 is up to 7,397 today, rising nearly 8% year to date, but there are 16 undervalued stocks in the UK
08/03/2017Karen Kwok Budget 2017: FTSE 100 Winners and Losers
The FTSE 100 stayed flat following the UK Budget - with slight gains in banking and retailer stocks thanks to upbeat economic forecasts
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
19/05/2020Transfer inMr. Mazen Samih Taleb Darwazah0.0016,9530.00
13/05/2020SaleMr. Mazen Samih Taleb Darwazah2,450.001,350,00033,075,000.00
13/05/2020SaleMr. Said Darwazah2,450.001,350,00033,075,000.00
15/04/2020Transfer inMr. Mazen Samih Taleb Darwazah0.0019,3180.00

Company Profile

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.

Sector

Drug Manufacturers - Specialty & Generic

Index

FTSE 100 ,FTSE 350 ,FTSE All Share

Next Event 07/08/2020

Half-Yearly Results
Ratios
Comp
More ...
PER (E)13.66
Div Yld (E)1.72
PEG (E)1.79
ROCE21.55
Op Mrgn0.20
EPS Grwth0.58
Dividends
PreviousLatest
More ...
Record Date23/08/1920/03/20
Ex-Div22/08/1919/03/20
Paid23/09/1907/05/20
Amnt14.0024.22
Directors
More ...
Non-Executive DirectorDr. Pamela Josephine Kirby
Executive Director, Vice ChairmanMr. Mazen Samih Taleb Darwazah
Non-Executive DirectorMr. Mohammed Ali Khaldoun S Al-Husry
Executive Director, ChairmanMr. Said Darwazah
Executive Director, Chief Executive OfficerMr. Sigurdur Olafsson
Non-Executive DirectorMr. Robert Pickering
Non-Executive DirectorNina Henderson
Non-Executive Director, Senior Independent DirectorMr. Patrick Butler
Non-Executive DirectorMr. John Julius Castellani
Non-Executive DirectorMs. Cynthia L. Schwalm
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2020 Morningstar. All rights reserved.